-Among patients with cutaneous melanomas, the prevalence of hypothyroidism is high (7%), being greater in female patients (13.9%) than in male patients (2.4%) [3] . Unfortunately, clinical trials showing an improvement in the outcome of melanomas after levothyroxine therapy are missing. Until the above-mentioned studies are done, taking into account both the aggressivity of melanomas and the high prevalence of hypothyroidism mentioned above, I would suggest measurement of serum TSH in patients with recently diagnosed melanomas and achievement of partial TSH suppression with levothyroxine therapy in those with subclinical or overt hypothyroidism.
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Dear Sir,
In my view, an additional treatment indication for subclinical hypothyroidism (table 2 in Pearce et al. [1] ) might be represented by patients with melanomas, the most aggressive malignancy arising from the skin.
This suggestion is based on the following data: -Human melanoma cells express functional receptors for TSH [2] ; the same group demonstrated that cultured melanoma cells produce cAMP and activate the mitogen-activated protein kinase (MAPK) pathway in response to TSH, indicating that the TSH receptor is functional [2] . -TSH is a growth factor for human melanomas, but not for melanocytes [2] . It is important to note that the concentration of TSH used in the cAMP, MAPK, and proliferation experiments (cultured melanoma cells) was 10 mIU/l, a concentration typical of levels found in patients with early, subclinical hypothyroidism [2] .
